PIKFYVE: 1-phosphatidylinositol 3-phosphate 5-kinase
Dual specificity kinase implicated in myriad essential cellular processes such as maintenance of endomembrane homeostasis, and endocytic-vacuolar pathway, lysosomal trafficking, nuclear transport, stress- or hormone-induced signaling and cell cycle progression.
- Drugs that act on it: 1
- Approved: 0
- In phases 1 to 3: 1
- Sponsors: 1
Who is on it, and how far along
Every drug ChEMBL records acting on PIKFYVE, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| Apilimod | Phase 2 | Synta Pharmaceuticals Corp. | Small molecule | Inhibitor1-phosphatidylinositol 3-phosphate 5-kinase inhibitor | 0 |
- Fleck corneal dystrophy0.75
- Neurodegenerative disease0.56
- Lysosomal storage disease0.51
- Alzheimer disease0.50
- Parkinson disease0.50
- Alcohol drinking0.32
- Hereditary disease0.20
- Muscular disease0.15
- Preeclampsia0.14
- Mixed connective tissue disease0.13
- Response to xenobiotic stimulus0.13
- Poisoning0.13
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL1938222, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt Q9Y2I7, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets